
(11α,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid
CAS:
Ref. IN-DA0038GD
1g
A consultar
5g
A consultar
10g
A consultar
5mg
75,00€
25mg
150,00€
50mg
219,00€
100mg
271,00€
250mg
684,00€

- Fatty Acids
- Lipids
- APIs for research and impurities
- Immunology and Inflammation
- Neuroscience
- Chiral Organic Compounds
- Biochemicals and Reagents
- Cellular and Molecular Biology
Información del producto
Nombre:(11α,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid
Sinónimos:
- Alprostadil
- Caverject
- Edex
- Minprog
- Muse
- Prostavasin
- Sugiran
- Vasaprostan
- Viridal
- alprostadil
- Caverject
- Edex
- Muse
- Alprostadilum
- Femprox
- Befar
- Liprostin
- Prostandin
- Vitaros
- Prostavasin
- Topiglan
- Vasaprostan
- Alprostadil(Caverject)
- Minprog
- (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
- Lipoprost
- Prostivas
- Alista
- Prink
- 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid
- (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
- 9-oxo-11R,15S-dihydroxy-13E-prostaenoic acid
- 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
- Sugiran
- Viridal
- (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid
- 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid
- Promostan
- FemLife
- RayVa
- Prostaglandine E
- Caverject Impulse
- 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoic acid
- 7-[(1r,3r)-3-Hydroxy-2-[(1e,3s)-3-Hydroxyoct-1-En-1-Yl]-5-Oxocyclopentyl]heptanoic Acid
- 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
- l-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
- Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-
- Alprostadil(usan)
- (1R,2R,3R)-3-Hydroxy-2-((E)-(3S)-3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
- (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate
- 11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid
- Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, l-
- (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid
- 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid
- Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,13E,15S)-
- Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer
- 11,15-Dihydroxy-9-oxoprost-13-en-1-oate
- (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoate
- (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoic acid
- (13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoic acid
- (11?,13E,15S)-11,15-Dihydroxy-9-oxo-prost-13-en-1-oic acid
- (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoic acid
- 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate
- (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate
- (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid
- (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate
- (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid
- (11alpha,12alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
- Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, (-)-
- 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]hepta noic acid
- Prostin
- Lipo-alprostadil
- Ver más sinónimos
Marca:Indagoo
Aviso:Nuestros productos están destinados únicamente para uso en laboratorio. Para cualquier otro uso, por favor contáctenos.
Propiedades químicas
Peso molecular:354.4810
Fórmula:C20H34O5
Pureza:98%
Color/Forma:Solid
InChI:InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
Clave InChI:GMVPRGQOIOIIMI-DWKJAMRDSA-N
Consulta técnica sobre: (11α,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid
Use el carrito para solicitar presupuestos o pedidos
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.